Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014

Overview

Journal Biol Blood Marrow Transplant

Date 2016 Jan 26

PMID 26806585

Citations 7

Authors

Monzr M Al Malki

Mary Horowitz

Rupert Handgretinger

Wing Leung

Denis-Claude Roy

Xiao-Jun Huang

Ephraim Fuchs

Franco Locatelli

Didier Blaise

Shin Mineishi

Massimo Martelli

Jeffrey Miller

Carl June

Hui-Sheng Ai

Leo Luznik

Domenico Mavilio

Enrico Lugli

Marcel R M van den Brink

Richard E Champlin

Stefan O Ciurea

Affiliations

Soon will be listed here.

Abstract

Significant progress has been made over the past decade in haploidentical transplantation, with the development of novel methods to control intense alloreactive reactions generated in the major HLA-mismatched setting. Application of post-transplantation cyclophosphamide has gained worldwide acceptance as an effective and low-cost way to perform this type of transplantation, with outcomes now similar to those from HLA-matched unrelated donors. These advances have resulted in improved treatment-related mortality, whereas disease relapse has emerged as the most common cause of treatment failure. In addition, improvements in immunologic reconstitution after transplantation are much needed, not only in haploidentical transplantation but in all forms of stem cell transplantation. This symposium has focused on some of the most promising methods to control alloreactivity in this form of transplantation and application of cellular therapy to prevent disease relapse after transplantation, as well as understanding immunologic reconstitution and foreseeable approaches to improve immune recovery after transplantation.

Citing Articles

The Evolution of T Cell Depleted Haploidentical Transplantation.

Aversa F, Pierini A, Ruggeri L, Martelli M, Velardi A Front Immunol. 2019; 10:2769.

PMID: 31827475 PMC: 6890606. DOI: 10.3389/fimmu.2019.02769.

The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation.

Ciurea S, Al Malki M, Kongtim P, Fuchs E, Luznik L, Huang X Bone Marrow Transplant. 2019; 55(1):12-24.

PMID: 30833742 DOI: 10.1038/s41409-019-0499-z.

Defining success with cellular therapeutics: the current landscape for clinical end point and toxicity analysis.

Kean L Blood. 2018; 131(24):2630-2639.

PMID: 29728399 PMC: 6032897. DOI: 10.1182/blood-2018-02-785881.

Advances in the Use of Regulatory T-Cells for the Prevention and Therapy of Graft-vs.-Host Disease.

Ramlal R, Hildebrandt G Biomedicines. 2017; 5(2).

PMID: 28536366 PMC: 5489809. DOI: 10.3390/biomedicines5020023.

Haploidentical Related Donor Hematopoietic Stem Cell Transplantation for Dedicator-of-Cytokinesis 8 Deficiency Using Post-Transplantation Cyclophosphamide.

Shah N, Freeman A, Su H, Cole K, Parta M, Moutsopoulos N Biol Blood Marrow Transplant. 2017; 23(6):980-990.

PMID: 28288951 PMC: 5757872. DOI: 10.1016/j.bbmt.2017.03.016.

References

Raiola A, Dominietto A, Varaldo R, Ghiso A, Galaverna F, Bramanti S . Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin's lymphoma. Bone Marrow Transplant. 2013; 49(2):190-4. DOI: 10.1038/bmt.2013.166. View

Lee S, Klein J, Haagenson M, Baxter-Lowe L, Confer D, Eapen M . High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007; 110(13):4576-83. DOI: 10.1182/blood-2007-06-097386. View

Vallera D, Zhang B, Gleason M, Oh S, Weiner L, Kaufman D . Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biother Radiopharm. 2013; 28(4):274-82. PMC: 4209492. DOI: 10.1089/cbr.2012.1329. View

Lugli E, Dominguez M, Gattinoni L, Chattopadhyay P, Bolton D, Song K . Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest. 2013; 123(2):594-9. PMC: 3561805. DOI: 10.1172/JCI66327. View

Heng T, Goldberg G, Gray D, Sutherland J, Chidgey A, Boyd R . Effects of castration on thymocyte development in two different models of thymic involution. J Immunol. 2005; 175(5):2982-93. DOI: 10.4049/jimmunol.175.5.2982. View

Gleason M, Verneris M, Todhunter D, Zhang B, McCullar V, Zhou S . Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol Cancer Ther. 2012; 11(12):2674-84. PMC: 3519950. DOI: 10.1158/1535-7163.MCT-12-0692. View

Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R . IL-22 increases the innate immunity of tissues. Immunity. 2004; 21(2):241-54. DOI: 10.1016/j.immuni.2004.07.007. View

Luznik L, Fuchs E . High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res. 2010; 47(1-3):65-77. PMC: 2892158. DOI: 10.1007/s12026-009-8139-0. View

Solomon S, Sizemore C, Sanacore M, Zhang X, Brown S, Holland H . Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free.... Biol Blood Marrow Transplant. 2012; 18(12):1859-66. DOI: 10.1016/j.bbmt.2012.06.019. View

10.

Kochenderfer J, Dudley M, Carpenter R, Kassim S, Rose J, Telford W . Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013; 122(25):4129-39. PMC: 3862276. DOI: 10.1182/blood-2013-08-519413. View

11.

Zenewicz L, Yancopoulos G, Valenzuela D, Murphy A, Stevens S, Flavell R . Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity. 2008; 29(6):947-57. PMC: 3269819. DOI: 10.1016/j.immuni.2008.11.003. View

12.

Kanakry C, Fuchs E, Luznik L . Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2015; 13(1):10-24. PMC: 4695979. DOI: 10.1038/nrclinonc.2015.128. View

13.

Oh S, Perera L, Burke D, Waldmann T, Berzofsky J . IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells. Proc Natl Acad Sci U S A. 2004; 101(42):15154-9. PMC: 524066. DOI: 10.1073/pnas.0406649101. View

14.

Porter D . The graft-versus-tumor potential of allogeneic cell therapy: an update on donor leukocyte infusions and nonmyeloablative allogeneic stem cell transplantation. J Hematother Stem Cell Res. 2001; 10(4):465-80. DOI: 10.1089/15258160152509082. View

15.

Dudakov J, Goldberg G, Reiseger J, Vlahos K, Chidgey A, Boyd R . Sex steroid ablation enhances hematopoietic recovery following cytotoxic antineoplastic therapy in aged mice. J Immunol. 2009; 183(11):7084-94. DOI: 10.4049/jimmunol.0900196. View

16.

Sanos S, Vonarbourg C, Mortha A, Diefenbach A . Control of epithelial cell function by interleukin-22-producing RORγt+ innate lymphoid cells. Immunology. 2011; 132(4):453-65. PMC: 3075499. DOI: 10.1111/j.1365-2567.2011.03410.x. View

17.

Kanakry J, Kasamon Y, Gocke C, Tsai H, Davis-Sproul J, Ghosh N . Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant. 2013; 19(4):602-6. PMC: 4020434. DOI: 10.1016/j.bbmt.2013.01.006. View

18.

Denman C, Senyukov V, Somanchi S, Phatarpekar P, Kopp L, Johnson J . Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One. 2012; 7(1):e30264. PMC: 3261192. DOI: 10.1371/journal.pone.0030264. View

19.

Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. PMC: 4267531. DOI: 10.1056/NEJMoa1407222. View

20.

Zhu H, Zhang X, Qin Y, Liu D, Jiang H, Chen H . MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood. 2013; 121(20):4056-62. DOI: 10.1182/blood-2012-11-468348. View